Real-world analysis of survival outcomes in advanced EGFR-mutant NSCLC patients treated with platinum-pemetrexed after EGFR-TKI treatment failure

Introduction: EGFR tyrosine kinase inhibitors (TKIs) are the standard therapy for non-small-cell lung cancer (NSCLC) patients with EGFR-activating mutations in the first-line setting. Despite initial efficacy, resistance to EGFR-TKIs often develops, and platinum-based chemotherapy is the predominant...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Zong-Han Yao, Wei-Yu Liao, Chin-Yao Yang, Chao-Chi Ho, Jin-Yuan Shih, Kuan-Yu Chen, James Chih-Hsin Yang, Chong-Jen Yu
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Elsevier 2025-08-01
Rangatū:	Journal of the Formosan Medical Association
Ngā marau:	Non-small cell lung cancer Epidermal growth factor receptor Tyrosine kinase inhibitors Platinum doublet Pemetrexed
Urunga tuihono:	http://www.sciencedirect.com/science/article/pii/S0929664624003851
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!